Gilles Favre is Professor of Biochemistry and Medical Biology at the University of Toulouse; he is also Scientific Director and Director of the Medical Oncology Biology Laboratory at the Toulouse-Oncopole University Cancer Institute.
Lastly, Gilles Favre is also in charge of the SIGNATHER team at the CRCT. Gilles Favre’s research focuses on cell signalling in cancer, identification of therapeutic targets and translational research approaches for the discovery of new biomarkers.
He has made major contributions to the cell biology of protein isoprenylation and has been heavily involved in the pre-clinical and clinical development of prenyltransferase inhibitors in cancer therapy.

He has helped to elucidate the cellular functions of RHOGTPases in genotoxic stress, DNA damage response and tumour progression. Recently, he has developed new strategies to control the functions of RAS family super-proteins and reverse resistance to targeted therapies in lung cancer and melanoma. Gilles Favre is an active member of scientific societies including the American Association for Cancer Research (AACR). He has acquired a strong experience in the evaluation of research, both nationally and internationally, through his participation in the Scientific Councils of Inserm, INCa (Institut National du Cancer) and the Alberta Cancer Board (University of Edmonton, Canada).


Decision-making organization

International Scientific Council

Toulouse cancer research, grouped within a network whose legal framework is the Public Interest Group (GIP) Toulouse University Cancer Institute (IUCT), has set up a unique International Scientific Board (ISC) to help structure local research and care. The current ISC is composed of 13 French and foreign members, clinicians and researchers, but other personalities may be contacted to reinforce the SAB according to the new research fields to be assessed.

The SAB’s main missions are to:

  • to advise on the scientific strategy to increase the visibility and attractiveness of the Toulouse site – to evaluate the medical-scientific activity of the research and care programs.
  • to evaluate projects submitted in response to internal AAPs (those of the IUCT, IUCT-Oncopole and CRCT, and/or the Toulouse Cancer Santé Foundation) and applications from teams on the site.

More specifically, in the context of the CRCT, the ISC has a mission to analyse and advise on the CRCT’s strategy and scientific project, on its recruitment policy, and also on the Unit’s renewal project, prior to the evaluation of the teams by the national authorities.

The ISC, by playing its role at the same time on the CRCT, the Research College of the GIP IUCT and the Toulouse Cancer Santé Foundation, has a global vision which enables it to appreciate the priorities to be supported and the initiatives to be encouraged.



Centro Nacional de Investigaciones Oncologicas
Madrid, Espagne
Learn more

Université paris-Sud
Paris, France
Learn more

Institut Pasteur
Paris, France
Learn more

EGLY Jean-Marc (Président)
Institut de Génétique et de Biologie Moléculaire et Cellulaire
Strasbourg, France
Learn more

GOUD Bruno
Institut Curie
Paris, France
Learn more

IMI Coordinator
Paris, France
Learn more

Rigshopitalet, Université de Copenhague
Copenhague, Danemark
Learn more

KAY Cyril
Université d’Alberta
Edmonton, Canada
Learn more

Oxford Institute for Radiation Oncology
Oxford, Royaume-Uni
Learn more

Institut de Recherche sur le Cancer et le Vieillissement
Nice, France
Learn more

Val d’Hebron Institute of Oncology
Barcelone, Espagne
Learn more

Institut Gustave Roussy
Villejuif, France
Learn more

Lugwig Institute
Bruxelles, Belgique
Learn more

Centre de Recherches en Cancérologie de Toulouse

Toulouse Cancer Research Center (Oncopole)

Toulouse - FR

Contact us

+33 5 82 74 15 75

Want to join
the CRCT team ?

Pin It on Pinterest